Healthcare [ 11/13 ] | Biotechnology [ 94/159 ]
NASDAQ | Common Stock
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States.
The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014.
Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 23 | -0.08 Increased by +96.36% | -0.09 Increased by +11.11% |
| Aug 14, 23 | -0.05 Increased by +97.73% | -0.1 Increased by +50% |
| May 15, 23 | -0.15 Decreased by -36.36% | -0.37 Increased by +59.46% |
| Mar 31, 23 | -1.73 Decreased by -116.25% | -2.28 Increased by +24.12% |
| Nov 10, 22 | -2.2 Increased by +26.67% | -2.1 Decreased by -4.76% |
| Aug 11, 22 | -2.2 Decreased by -10% | -1.8 Decreased by -22.22% |
| May 16, 22 | -0.11 Increased by +99.66% | -0.09 Decreased by -22.22% |
| Mar 31, 22 | -0.8 Increased by +93.33% | -3.2 Increased by +75% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by N/A% | -1.97 M Increased by +77.46% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | -1.11 M Increased by +87.11% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -4.35 M Increased by +46.67% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by N/A% | -2.54 M Increased by +20.74% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -8.75 M Decreased by -130.36% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -8.58 M Decreased by -399.93% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -8.16 M Increased by +65.63% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0 Decreased by N/A% | -3.21 M Decreased by -13.46% | Decreased by N/A% Decreased by N/A% |